Cost-per-responder analysis of tralokinumab versus dupilumab in patients with moderate-to-severe atopic dermatitis in the US and Canada

被引：0
|
作者：
Wu, Jashin J. [1 ]
Balu, Sanjeev [2 ]
Larsen, Nikolaj Birk [3 ]
Pulleyblank, Ryan [3 ]
Stromkjaer, Liv [3 ]
Quah, Aron [4 ]
Wiseman, Marni [5 ,6 ]
机构：
[1] Univ Miami, Miller Sch Med, Dept Dermatol, Miami, FL USA
[2] LEO Pharma, Madison, NJ USA
[3] NHTA ApS, Copenhagen, Denmark
[4] LEO Pharma, N York, ON, Canada
[5] Univ Manitoba, Dept Med, Sect Dermatol, Winnipeg, MB, Canada
[6] Wiseman Dermatol Res, Winnipeg, MB, Canada
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷
关键词：
matching-adjusted indirect comparison; moderate-to-severe; tralokinumab;
D O I：
10.1093/bjd/ljad498.044
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
544
引用
收藏
页码：II42 / II43
页数：2
相关论文
共 50 条
  • [31] Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Torres, Tiago
    Petersen, Anne Sohrt
    Ivens, Ulla
    Vilaro, Albert Bosch
    Stinson, John
    Carrascosa, Jose Manuel
    DERMATOLOGY AND THERAPY, 2024, 14 (04) : 983 - 992
  • [32] Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study
    Keow, Samantha
    Abu-Hilal, Mohannad
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (04) : 734 - 735
  • [33] Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children
    Parker, Jennifer J.
    Sugarman, Jeffrey L.
    Silverberg, Nanette B.
    Gonzalez, Mercedes Elena
    Ramien, Michele L.
    Teng, Joyce M. C.
    Paller, Amy S.
    PEDIATRIC DERMATOLOGY, 2021, 38 (06) : 1500 - 1505
  • [34] LONG-TERM EFFICACY OF TRALOKINUMAB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Wollenberg, Andreas
    Paller, Amy S.
    Bewley, Anthony
    Cork, Michael
    Hong, Chih-Ho
    Soong, Weily
    Oland, Christian Bjerregard
    Taveira, Christian Moreira
    Gjerum, Le
    Blauvelt, Andrew
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 54 - 54
  • [35] Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy
    Pompilio, Giuseppe
    Integlia, Davide
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2022, 9 : 138 - 145
  • [36] COST PER RESPONDER OF USTEKINUMAB VERSUS ETANERCEPT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS FROM THE ACCEPT TRIAL
    Feldman, S. R.
    Augustin, M.
    Martin, S.
    Szapary, P.
    Schenkel, B.
    VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
  • [37] Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients
    Achten, Roselie
    Thijs, Judith
    van Luijk, Chantal
    Knol, Edward
    Delemarre, Eveline
    de Graaf, Marlies
    Bakker, Daphne
    de Boer, Joke
    van Wijk, Femke
    de Bruin-Weller, Marjolein
    CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (02): : 239 - 243
  • [38] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Zheng, Y.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 72 - 72
  • [39] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Xu, Xinghua
    Zheng, Yi
    Zhang, Xin
    He, Yanling
    Li, Chengxin
    ONCOTARGET, 2017, 8 (65) : 108480 - 108491
  • [40] Dupilumab Improves Skin Lipid Barrier in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis
    Bronova, Irina
    Berdyshev, Evgeny
    Goleva, Elena
    Danby, Simon
    Bronoff, Anna Sofia
    Richers, Brittany
    Garcia, Shannon
    Gama, Marco Ramirez
    Taylor, Patricia
    Zahn, Joseph
    Agueusop, Inoncent
    Bafna, Shantanu
    Boguniewicz, Mark
    Ong, Peck
    Zhang, Annie
    Cork, Michael
    Leung, Donald
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB5 - AB5
12345